Pan Lingxiao, Zheng Wenbo, Ye Xigang, Chen Lun, Ke Yaohua, Wan Minghui, Tang Wei, Gao Jin, Zhang Xiaoshen
Department of Breast Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.
Department of Breast Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.
Clin Breast Cancer. 2014 Dec;14(6):435-41. doi: 10.1016/j.clbc.2014.04.002. Epub 2014 Jun 3.
Despite the advancement and increasing use of breast-conserving surgery, mastectomies, including nipple-sparing mastectomy (NSM), are still carried out in a portion of breast cancer patients. However, the role of NSM is still controversial, mainly because of concern about the oncologic safety of the nipple-areola complex (NAC). INTRABEAM (Carl Zeiss, Oberkochen, Germany) is the most widely used mobile intraoperative radiotherapy (IORT) device to date. This pilot study aims to broaden the application of the INTRABEAM system for breast cancer, investigating the feasibility of INTRABEAM IORT in NSM with breast reconstruction.
From December 2012 to June 2013, 7 female patients with breast cancer were enrolled in the study. NSM with or without axillary dissection was performed first. After confirming negative retroareolar frozen section results and no poor local bleeding in the NAC, INTRABEAM IORT was carried out with a single dose of 16 Gy, followed by breast reconstruction. The complications and short-term outcomes were assessed.
The median radiation time was 13 minutes 14 seconds in the 7 cases. One patient complained of mild pain in the radiation field on the skin in the first 2 weeks. All 7 patients were followed for a median of 7 months. No acute radiation injury with symptoms (heart, lung, or hematologic system), NAC necrosis, local recurrence, or metastasis was observed. Although every patient had reduction in NAC sensitivity, the contours of the breasts (including the NAC) were satisfactory.
INTRABEAM IORT may be a feasible and convenient approach for NSM with breast reconstruction in patients with breast cancer.
尽管保乳手术不断发展且应用日益广泛,但仍有一部分乳腺癌患者接受乳房切除术,包括保留乳头的乳房切除术(NSM)。然而,NSM的作用仍存在争议,主要是因为担心乳头乳晕复合体(NAC)的肿瘤学安全性。INTRABEAM(德国奥伯科亨卡尔蔡司公司)是迄今为止使用最广泛的移动式术中放疗(IORT)设备。本前瞻性研究旨在扩大INTRABEAM系统在乳腺癌中的应用,探讨INTRABEAM IORT在NSM联合乳房重建中的可行性。
2012年12月至2013年6月,7例女性乳腺癌患者纳入本研究。首先进行有或无腋窝淋巴结清扫的NSM。在确认乳晕后切缘冰冻切片结果为阴性且NAC无严重局部出血后,采用单次剂量16 Gy进行INTRABEAM IORT,随后进行乳房重建。评估并发症和短期结局。
7例患者的中位放疗时间为13分14秒。1例患者在最初2周内抱怨放疗区域皮肤有轻度疼痛。所有7例患者的中位随访时间为7个月。未观察到有症状的急性放射损伤(心脏、肺或血液系统)、NAC坏死、局部复发或转移。虽然每位患者的NAC敏感性均降低,但乳房(包括NAC)外形满意。
INTRABEAM IORT对于乳腺癌患者NSM联合乳房重建可能是一种可行且便捷的方法。